Skip to main content
65°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MediWound Ltd. - Ordinary Shares
(NQ:
MDWD
)
16.76
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MediWound Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
September 02, 2025
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 20, 2025
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Revenue Jumps 43% in Q2
August 14, 2025
Via
The Motley Fool
MediWound (MDWD) Q2 2025 Earnings Call Transcript
August 14, 2025
Via
The Motley Fool
Topics
Earnings
Earnings Scheduled For August 14, 2025
August 14, 2025
Via
Benzinga
Earnings Outlook For MediWound
May 20, 2025
Via
Benzinga
Earnings Preview: MediWound
November 25, 2024
Via
Benzinga
MediWound Ltd (NASDAQ:MDWD) Reports Mixed Q2 2025 Results with Revenue Growth but Wider-Than-Expected Losses
August 14, 2025
MediWound's Q2 2025 results show mixed performance: $5.7M revenue (+43% QoQ) missed estimates, but shares rose 5% on NexoBrid growth and EscharEx progress.
Via
Chartmill
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
August 13, 2025
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report Second Quarter 2025 Financial Results
August 04, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday
May 22, 2025
Via
Benzinga
MediWound (MDWD) Q1 2025 Earnings Call Transcript
May 21, 2025
Via
The Motley Fool
Topics
Earnings
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 21, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Earnings Scheduled For May 21, 2025
May 21, 2025
Via
Benzinga
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
May 13, 2025
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report First Quarter 2025 Financial Results
May 05, 2025
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
April 28, 2025
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 19, 2025
From
MediWound Ltd.
Via
GlobeNewswire
Earnings Scheduled For March 19, 2025
March 19, 2025
Via
Benzinga
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025
Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
February 28, 2025
Via
Benzinga
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
February 25, 2025
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
February 24, 2025
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
February 12, 2025
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
December 17, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday
November 27, 2024
Via
Benzinga
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
November 26, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Earnings Scheduled For November 26, 2024
November 26, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.